Tag: Abbott
DRS combination of scaffold and antirestenotic drug will “really advance” treatment...
Principal investigators of the LIFE-BTK randomised controlled trial delve into the technological improvements underpinning the Esprit drug-eluting resorbable scaffold (DRS; Abbott) from its previous...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough...
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 October, San Francisco, USA). The data show that, in...
Drug-eluting resorbable scaffolds “among most exciting technologies” in treatment of peripheral...
A temporary mechanical support with antiproliferative properties might combine two particular treatment qualities to fill a gap in the treatment armamentarium for peripheral arterial...
JETi registry provides “remarkable results” for peripheral thrombectomy system
Presenting “remarkable results” from the JETi registry—a prospective, multicenter, observational study which collected real-world data on the safety, performance and clinical benefits of the...
Vascular News’ top 10 most popular stories of February 2023
February's top 10 includes the announcement that Abbott is to acquire Cardiovascular Systems, results of the PRESERVE study on the safety and effectiveness of...
Vascular News’ top 10 most popular stories of October 2021
New data from a head-to-head, randomised trial comparing vascular closure devices, highlights from CX Aortic Vienna 2021 (5–7 October, broadcast) and an interview with past Society...
Vascular News’ top 10 most popular stories of September 2021
September's top 10 features five-year ACST-2 results, a new tool to assess amputation risk following popliteal vascular injury, and an interview highlighting the questions...
Abbott expands peripheral vascular offerings with acquisition of Walk Vascular
Abbott announced today that it has acquired Walk Vascular, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to...
No safety concerns and favourable patency at two years with Absorb...
The Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) can be used for the treatment of chronic limb-threatening ischaemia (CLTI) patients in infrapopliteal arteries with...
First patients enrolled in SUPERSURG study of Supera peripheral stent system
ID3 Medical Belgium has announced the first two enrolments in the SUPERSURG study to investigate the safety and efficacy of Abbott's Supera peripheral stent...
VIVA 2019: ABSORB BVS achieves “excellent” long-term patency and freedom from...
Ramon Varcoe today announced positive five-year results of the ABSORB BTK trial at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA...
VIVA 2019: CFA disease can be treated endovascularly with Supera stent
Two-year data confirm that common femoral artery (CFA) disease can be treated endovascularly with the Supera stent (Abbott). Results of the VMI-CFA study were...
Perclose ProGlide suture-mediated closure system FDA approval
Abbott has gained FDA approval for its Perclose Proglide suture-mediated closure system. The device is designed to close access sites created by large bore...
Surmodics partners with Abbott to develop their next-generation DCB
Abbott and Surmodics have announced an agreement whereby Abbott will have exclusive worldwide commercialisation rights for Surmodics' SurVeil drug-coated balloon (DCB) to treat the superficial...
InspireMD announces expansion of its distribution network for CGuard EPS
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
Analysis of percutaneous large-bore arterial access closure shows fewer adverse outcomes...
Percutaneous closure of large-bore arterial access sites using the Perclose ProGlide suture-mediated closure device (Abbott Vascular) is associated with significantly lower rates of blood...
SUPERSUB trial update and precise stent placement with the Presto technique
At LINC 2017 (24–27 January, Leipzig, Germany), Luis Mariano Palena (Policlinico Abano Terme, Abano Terme, Italy) presented an update on the SUPERSUB trial, which...
Terumo completes acquisition of vascular closure business and other assets of...
Terumo has announced that it has completed its acquisition of certain assets owned by Abbott and St Jude Medical.
Terumo has acquired the Angio-Seal and...
Abbott completes the acquisition of St Jude Medical
Abbott has now completed the acquisition of St Jude Medical. The Abbott press release announcing the completion of the acquisition said, “The transaction provides...
Abbott acquisition of St Jude Medical set to close on 4...
Abbott has announced its intention to close the acquisition of St Jude Medical on Wednesday, 4 January 2017. The announcement follows receipt of all...
Terumo signs to acquire St Jude Medical and Abbott’s vascular closure...
Terumo has reached an agreement with Abbott and St Jude Medical to acquire certain products owned by both for a total of US$1.12 billion.
Based...
St Jude Medical shareholders approve merger with Abbott
St Jude Medical has announced that, based on the preliminary voting results from St Jude Medical’s Annual Meeting of Shareholders held on 26 October, St...
SUPERFAST results show advantage of Supera for chronic total occlusions
New data from a propensity matched prospective study suggest the Supera stent (Abbott Vascular) delivers superior results when compared to older generation nitinol stents...
St Jude Medical and Abbott to sell portion of vascular closure...
Abbott and St Jude Medical have announced an agreement in principle to sell certain products to Terumo Corporation.
The transaction reflects a purchase price of...
